INNOVATIVE CELL THERAPIES (EGFF) (COVID-19)

Projektträger – zwischengeschaltetes Finanzinstitut

PLURISTEM GMBH

Ort

• Deutschland

Beschreibung

The promoter is a clinical-stage biotherapy company that use placental stem cells and its unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, haematological disorders and mucosal repair following a severe infection, as well as complications from COVID-19 infection.

Ziele

The proposed transaction will support R&D investments that are required in order to further advance the promoter's product pipeline and bring the products to market.

Sektor(en)

• Dienstleistungen - Erbringung von Freiberuflichen, Wissenschaftlichen und Technischen Dienstleistungen

Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

EUR 50 million

Gesamtkosten (voraussichtlicher Betrag)

EUR 100 million

Umweltaspekte

The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2014/52/EU amending 2011/92/EU. Full environmental details will be verified during the appraisal.

Auftragsvergabe

The promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

Projektstatus

Unterzeichnet - 29/04/2020